VISTIN PHARMA ASA: årsregnskap 2024 vs 2023
Grew 97887% on revenue
approved 2025-04-25; registry 2025-08-06; journal 2025 663301
Summary
What changed
Comparing Årsregnskap 2024 with 2023 for VISTIN PHARMA ASA. Revenue 438.3k NOK → 429.50m NOK (+97886.7%). Net result -2.98m NOK → -3.53m NOK. Equity 265.15m NOK → 184.03m NOK.
On the constructive side: revenue rose; operating result improved; cash rose. Pressures included: net result weakened; equity eroded.
Also worth watching: paid-in equity reduced; payroll increased; cogs moved. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 438.3k NOK to 429.50m NOK (+97886.7% YoY). Calculated
-
↑
Operating result improved
Operating result -6.98m NOK → -6.05m NOK (op. margin -1592.0% → -1.4%). Calculated
-
↑
Cash rose
Bank deposits 1.85m NOK → 5.93m NOK (+220.5% YoY). Calculated
What deteriorated
-
↓
Net result weakened
Net result -2.98m NOK → -3.53m NOK (net margin -680.8% → -0.8%). Calculated
-
↓
Equity eroded
Book equity 265.15m NOK → 184.03m NOK (equity ratio 99.6% → 98.6%). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 265.15m NOK → 184.03m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 2.15m NOK → 3.70m NOK (490% → 1% of revenue). Calculated
-
·
COGS moved
COGS / varekostnad 176.6k NOK → 149.97m NOK (+84799.0% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 113.1k NOK → 54.86m NOK. Reported fact